bipolar II disorder; bipolar depression

From Aaushi
Jump to navigation Jump to search

Clinical manifestations

Management

More general terms

References

  1. NEJM Knowledge+ Question of the Week. Aug 15, 2017 https://knowledgeplus.nejm.org/question-of-week/1288/
  2. 2.0 2.1 Sit DK, McGowan J, Wiltrout C et al. Adjunctive bright light therapy for bipolar depression: A randomized double-blind placebo-controlled trial. Am J Psychiatry 2017 Oct 3; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28969438 <Internet> http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.16101200
  3. 3.0 3.1 3.2 Savitz JB, Teague TK, Misaki M et al. Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018 Jan 24;8(1):27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29362444 Free PMC Article
  4. 4.0 4.1 Mehrpooya M et al. Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: A double-blind controlled clinical trial. J Clin Psychopharmacol 2018 Oct; 38:460. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30106880
  5. 5.0 5.1 Brooks M FDA Grants New Indication to Lumateperone (Caplyta) for Bipolar Depression. Medscape. December 20, 2021 https://www.medscape.com/viewarticle/965134
  6. 6.0 6.1 Aaronson ST, van der Vaart A, Miller T et al Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes. A Nonrandomized Controlled Trial. JAMA Psychiatry. Published online December 6, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38055270 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2812443
    Yaden DB, Gukasyan N, Nayak SM et al Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. JAMA Psychiatry. Published online December 6, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38055240 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2812445